Pancreatic Cancer Research

Clinical trialPhase 2Completed

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Outcome
Primary endpoint: no statistically significant difference (Hazard Ratio (HR) 1.23 (95% CI 0.85 to 1.78); p = 0.28, as posted; posted threshold 0.02)
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
27 October 2016
Ended
21 October 2021
Enrollment
123 participants
Sites
783
Primary outcomes
Overall Survival (OS)
Sponsor type
NIH
Results posted
29 September 2020
Last update
20 May 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Primary endpoint: no statistically significant difference (Hazard Ratio (HR) 1.23 (95% CI 0.85 to 1.78); p = 0.28, as posted; posted threshold 0.02)As posted on ClinicalTrials.gov ↗, registry record of 20 May 2026
OS
Overall Survival (OS)Arm I (Veliparib and mFOLFIRI): 5.4 (3.7 to 7.2), n = 59Arm II (FOLFIRI): 6.5 (5.6 to 7.8), n = 58Arm I (Veliparib and mFOLFIRI) vs Arm II (FOLFIRI): Hazard Ratio (HR) 1.23 (95% CI 0.85 to 1.78); p = 0.28; Log Rank (not statistically significant against the posted threshold 0.02; outcome 1, analysis 1)Values: median months, 95% Confidence IntervalTime frame: Up to 3 years
Participants
Arm I (Veliparib and mFOLFIRI): 59 started, 0 completedArm II (FOLFIRI): 58 started, 0 completed
Serious adverse events
Arm I Veliparib and mFOLFIRI: 23 of 56Arm II FOLFIRI: 6 of 50Participants with at least one serious adverse event, of those at risk, as posted
5 secondary outcomes
Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
Abdominal infection: Arm I Veliparib and mFOLFIRI 0, n=56; Arm II FOLFIRI 1, n=50 [Participants] (first of 41 rows)
PFS · Progression Free Survival (PFS)
Arm I (Veliparib and mFOLFIRI) 2.1 (1.9 to 2.4), n=59; Arm II (FOLFIRI) 2.9 (2.2 to 4.2), n=58 [median months, 99% Confidence Interval] Arm I (Veliparib and mFOLFIRI) vs Arm II (FOLFIRI): Hazard Ratio (HR) 1.39 (95% CI 0.96 to 2.02); p = 0.09; Log Rank
ORR · Overall Response Rate, ORR
Arm I (Veliparib and mFOLFIRI) 0.09 (0.01 to 0.16), n=57; Arm II (FOLFIRI) 0.10 (0.02 to 0.18), n=51 [proportion of participants, 95% Confidence Interval]
DCR · Disease Control Rate
Arm I (Veliparib and mFOLFIRI) 0.32 (0.19 to 0.44), n=57; Arm II (FOLFIRI) 0.47 (0.33 to 0.61), n=51 [proportion of participants, 95% Confidence Interval]
Duration of Response (DoR)
Arm I (Veliparib and mFOLFIRI) 3.4 (2.6 to 3.4), n=3; Arm II (FOLFIRI) 5.1 (2.2 to 5.2), n=3 [median months, 95% Confidence Interval]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This randomized phase II trial studies how well modified irinotecan hydrochloride, leucovorin calcium, fluorouracil (FOLFIRI) and veliparib as a second line of therapy work compared to FOLFIRI in treating patients with pancreatic cancer that has come back after a period of improvement (metastatic). Drugs used in chemotherapy, such as irinotecan hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether modified FOLFIRI and veliparib as second line therapy is more effective than FOLFIRI alone in treating metastatic pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

PRIMARY OBJECTIVES: I. To evaluate the overall survival (OS) of metastatic pancreatic cancer patients treated with fluorouracil, irinotecan (irinotecan hydrochloride), leucovorin (leucovorin calcium), (modified FOLFIRI) and ABT-888 (veliparib) compared to a control arm of fluorouracil, irinotecan, and leucovorin (FOLFIRI). SECONDARY OBJECTIVES: I. To evaluate the frequency and severity of toxicity associated with each of the treatment arms in this patient population. II. To evaluate the progression-free survival (PFS) in each of the treatment arms in this patient population. III. To evaluate the overall response rate (confirmed and unconfirmed; complete response + partial response), disease control rate (confirmed and unconfirmed; complete response + partial response + stable disease), and duration of response in each of the treatment arms in this patient population. TERTIARY OBJECTIVES: I. To evaluate if breast cancer, early onset (BRCA)1 and BRCA2 mutations (somatic or germline) are associated with improved clinical outcomes (overall survival \[OS\], progression-free survival \[PFS\] and overall response rates \[ORR\]) in each treatment arm. II. To evaluate the impact of homologous recombination deficiency (HRD) score on clinical outcomes in each treatment arm. III. To evaluate the impact of genomic alterations identified by the BROCA-homologous recombinant (HR) assay, other than BRCA1/2, on clinical outcomes in each treatment arm. IV. To bank tissue for future translational medicine studies. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive veliparib orally (PO) twice daily (BID) every 12 hours on days 1-7, irinotecan hydrochloride intravenously (IV) over 90-120 minutes on day 3, leucovorin calcium IV over 90-120 minutes on day 3, and fluorouracil IV over 46 hours on days 3-5. ARM II: Patients receive irinotecan hydrochloride IV over 90-120 minutes on day 1, leucovorin calcium IV over 90-120 minutes on day 1, and fluorouracil IV bolus over 15 minutes on days 1 and then over 46 hours on days 1-3. In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 3 years.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Overall Survival (OS) [Up to 3 years]. Median, months (95% Confidence Interval). Arm I (Veliparib and mFOLFIRI) (n=59): 5.4 (3.7 to 7.2); Arm II (FOLFIRI) (n=58): 6.5 (5.6 to 7.8). Analysis, Arm I (Veliparib and mFOLFIRI) vs Arm II (FOLFIRI): Hazard Ratio (HR) 1.23 (95% CI 0.85 to 1.78); p=0.28; Log Rank; superiority.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs [Duration of treatment and follow up until death or 3 years post registration]. Number, Participants. Abdominal infection: Arm I Veliparib and mFOLFIRI (n=56): 0; Arm II FOLFIRI (n=50): 1. Abdominal pain: Arm I Veliparib and mFOLFIRI (n=56): 2; Arm II FOLFIRI (n=50): 1. Acute coronary syndrome: Arm I Veliparib and mFOLFIRI (n=56): 1; Arm II FOLFIRI (n=50): 0. Alanine aminotransferase increased: Arm I Veliparib and mFOLFIRI (n=56): 2; Arm II FOLFIRI (n=50): 0. Alkaline phosphatase increased: Arm I Veliparib and mFOLFIRI (n=56): 2; Arm II FOLFIRI (n=50): 3. Anemia: Arm I Veliparib and mFOLFIRI (n=56): 4; Arm II FOLFIRI (n=50): 5. Anorexia: Arm I Veliparib and mFOLFIRI (n=56): 3; Arm II FOLFIRI (n=50): 0. Aspartate aminotransferase increased: Arm I Veliparib and mFOLFIRI (n=56): 1; Arm II FOLFIRI (n=50): 1. Atrial fibrillation: Arm I Veliparib and mFOLFIRI (n=56): 0; Arm II FOLFIRI (n=50): 1. Atrial flutter: Arm I Veliparib and mFOLFIRI (n=56): 0; Arm II FOLFIRI (n=50): 1. Blood bilirubin increased: Arm I Veliparib and mFOLFIRI (n=56): 4; Arm II FOLFIRI (n=50): 5. Cardiac disorders - Other, specify: Arm I Veliparib and mFOLFIRI (n=56): 1; Arm II FOLFIRI (n=50): 0. Catheter related infection: Arm I Veliparib and mFOLFIRI (n=56): 1; Arm II FOLFIRI (n=50): 0. Confusion: Arm I Veliparib and mFOLFIRI (n=56): 0; Arm II FOLFIRI (n=50): 1. Cough: Arm I Veliparib and mFOLFIRI (n=56): 0; Arm II FOLFIRI (n=50): 1. Dehydration: Arm I Veliparib and mFOLFIRI (n=56): 6; Arm II FOLFIRI (n=50): 1. Device related infection: Arm I Veliparib and mFOLFIRI (n=56): 1; Arm II FOLFIRI (n=50): 0. Diarrhea: Arm I Veliparib and mFOLFIRI (n=56): 6; Arm II FOLFIRI (n=50): 3. Dyspnea: Arm I Veliparib and mFOLFIRI (n=56): 1; Arm II FOLFIRI (n=50): 0. Enterocolitis infectious: Arm I Veliparib and mFOLFIRI (n=56): 0; Arm II FOLFIRI (n=50): 1. Fall: Arm I Veliparib and mFOLFIRI (n=56): 0; Arm II FOLFIRI (n=50): 1. Fatigue: Arm I Veliparib and mFOLFIRI (n=56): 10; Arm II FOLFIRI (n=50): 3. Febrile neutropenia: Arm I Veliparib and mFOLFIRI (n=56): 1; Arm II FOLFIRI (n=50): 1. Fever: Arm I Veliparib and mFOLFIRI (n=56): 0; Arm II FOLFIRI (n=50): 1. Generalized muscle weakness: Arm I Veliparib and mFOLFIRI (n=56): 2; Arm II FOLFIRI (n=50): 1. Hyperglycemia: Arm I Veliparib and mFOLFIRI (n=56): 1; Arm II FOLFIRI (n=50): 1. Hypertension: Arm I Veliparib and mFOLFIRI (n=56): 1; Arm II FOLFIRI (n=50): 2. Hypokalemia: Arm I Veliparib and mFOLFIRI (n=56): 2; Arm II FOLFIRI (n=50): 1. Hyponatremia: Arm I Veliparib and mFOLFIRI (n=56): 2; Arm II FOLFIRI (n=50): 3. Hypotension: Arm I Veliparib and mFOLFIRI (n=56): 0; Arm II FOLFIRI (n=50): 1. Infections and infestations - Other, specify: Arm I Veliparib and mFOLFIRI (n=56): 2; Arm II FOLFIRI (n=50): 1. Lymphocyte count decreased: Arm I Veliparib and mFOLFIRI (n=56): 3; Arm II FOLFIRI (n=50): 6. Mucositis oral: Arm I Veliparib and mFOLFIRI (n=56): 0; Arm II FOLFI

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression Free Survival (PFS) [From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years]. Median, months (99% Confidence Interval). Arm I (Veliparib and mFOLFIRI) (n=59): 2.1 (1.9 to 2.4); Arm II (FOLFIRI) (n=58): 2.9 (2.2 to 4.2). Analysis, Arm I (Veliparib and mFOLFIRI) vs Arm II (FOLFIRI): Hazard Ratio (HR) 1.39 (95% CI 0.96 to 2.02); p=0.09; Log Rank; superiority.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Response Rate, ORR [Up to 3 years post registration]. Number, proportion of participants (95% Confidence Interval). Arm I (Veliparib and mFOLFIRI) (n=57): 0.09 (0.01 to 0.16); Arm II (FOLFIRI) (n=51): 0.10 (0.02 to 0.18).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Disease Control Rate [Up to 3 years post registration]. Number, proportion of participants (95% Confidence Interval). Arm I (Veliparib and mFOLFIRI) (n=57): 0.32 (0.19 to 0.44); Arm II (FOLFIRI) (n=51): 0.47 (0.33 to 0.61).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Duration of Response (DoR) [Up to 3 years post registration]. Median, months (95% Confidence Interval). Arm I (Veliparib and mFOLFIRI) (n=3): 3.4 (2.6 to 3.4); Arm II (FOLFIRI) (n=3): 5.1 (2.2 to 5.2).